(S,R,S)-AHPC-PEG3-N3

Background Introduction

(S,R,S)-AHPC-PEG3-N3 is a next-generation E3 ligase ligand-linker conjugate designed specifically for PROTAC (Proteolysis Targeting Chimera) and targeted protein degradation applications. Featuring an (S,R,S)-AHPC-based CRBN (cereblon) E3 ligase ligand, this compound is conjugated via a PEG3 (triethylene glycol) spacer to an azide (N3) functional group, providing both biocompatibility and enhanced solubility. The azido group enables rapid and reliable click chemistry-mediated conjugation to various target protein ligands, paving the way for efficient, modular PROTAC development.

Mechanism

(S,R,S)-AHPC-PEG3-N3 operates by binding selectively to the cereblon E3 ubiquitin ligase through its (S,R,S)-AHPC motif. The PEG3 linker offers ideal flexibility and reduced steric hindrance, improving both cellular permeability and solubility of the final PROTAC construct. The azide group at the terminal end of the linker allows for facile conjugation to alkyne-modified ligands or biomolecules via copper-catalyzed azide-alkyne cycloaddition (CuAAC, 'click chemistry'). Once assembled into a bifunctional PROTAC molecule, it bridges the target protein and cereblon E3 ligase, facilitating ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

(S,R,S)-AHPC-PEG3-N3 is ideally suited for the development of novel PROTACs, molecular glue degraders, and related targeted protein degradation therapies. Researchers can utilize this compound's click-ready azide functionality for customizable and high-throughput library generation of protein degraders. It is widely employed in drug discovery and chemical biology studies aimed at validating new therapeutic targets or rapidly optimizing PROTAC constructs. Its application extends to in vitro, cellular, and animal model studies for understanding disease biology and leveraging targeted protein degradation as a therapeutic strategy.

The E3 Ligase Ligand-Linker Conjugate, (S,R,S)-AHPC-PEG3-N3, plays a crucial role in PROTACs by facilitating the targeted degradation of proteins through the ubiquitin-proteasome system. This conjugate is characterized by its efficient E3 ligase recruitment, adaptable linker, and compatibility with various target protein ligands, enhancing the specificity and efficacy of protein degradation.

Linker: The linker in this molecule is a PEG3 moiety, offering moderate length and flexibility, which aids in maintaining an optimal distance between the ligand and target protein. Its non-cleavable nature ensures stability during the degradation process, making it suitable for a wide range of experimental conditions.

Ligand: The ligand component is based on the AHPC scaffold, renowned for its high-affinity binding to the VHL E3 ligase. Its stereochemistry, specifically the (S,R,S) configuration, ensures precise molecular recognition, which is critical for effective ubiquitination and subsequent proteasomal degradation of the target protein.

Reactive Site: The azide group (N3) serves as the reactive site in this molecule, facilitating bioorthogonal reactions such as click chemistry. This site allows for efficient coupling with alkyne-functionalized target protein ligands, enabling the creation of robust PROTACs for targeted protein degradation studies.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is an alkyne-functionalized moiety. This warhead is advantageous due to its ability to undergo click reactions with the azide group, forming stable triazole linkages. Such linkages are crucial for the development of PROTACs that can selectively degrade disease-associated proteins, offering valuable insights for therapeutic research and drug discovery.